Hims & Hers rises on partnership with Novo Nordisk to sell Wegovy on its platform

Shares of Hims & Hers HIMS.N rise 43% to $40.73 premarket

Novo Nordisk NOVOb.CO has partnered with the telehealth firm to sell its popular weight loss drug through a bundled offering on HIMS platform

Starting this week, customers will get access to the offerings of all dose strengths of Wegovy and a membership at a price starting at $599 per month - HIMS

HIMS says it will continue to offer personalized compounded versions of semaglutide, the active ingredient in Novo's Wegovy

Earlier this month, HIMS said it plans to sell Eli Lilly's LLY.N Zepbound on its platform

Up to last close, HIMS up 17.8% YTD